Identification of Thyroid Hormone Receptor Binding Sites and Target Genes Using ChIP-on-Chip in Developing Mouse Cerebellum

Hongyan Dong1*, Carole L. Yauk2, Andrea Rowan-Carroll2, Seo-Hee You3, R. Thomas Zoeller3, Iain Lambert4, Michael G. Wade1

1 Hazard Identification Division, EHSRB, Health Canada, Ottawa, Ontario, Canada, 2 Mechanistic Study Division, EHSRB, Health Canada, Ottawa, Ontario, Canada, 3 Molecular & Cellular Biology Program, University of Massachusetts, Amherst, Massachusetts, United States of America, 4 Department of Biology, Carleton University, Ottawa, Ontario, Canada

Abstract

Thyroid hormone (TH) is critical to normal brain development, but the mechanisms operating in this process are poorly understood. We used chromatin immunoprecipitation to enrich regions of DNA bound to thyroid receptor beta (TRβ) of mouse cerebellum sampled on postnatal day 15. Enriched target was hybridized to promoter microarrays (ChIP-on-chip) spanning −8 kb to +2 kb of the transcription start site (TSS) of 5000 genes. We identified 91 genes with TR binding sites. Roughly half of the sites were located in introns, while 30% were located within 1 kb upstream (5′) of the TSS. Of these genes, 83% had known function included genes involved in apoptosis, neurodevelopment, metabolism and signal transduction. Two genes, MBP and CD44, are known to contain TR binding sites upstream of the coding region of myelin associated glycoprotein was demonstrated to be TR-responsive using a luciferase expression system. Motif searches did not identify any classic binding elements, indicating that not all TR binding sites conform to variations of the classic form. These findings provide mechanistic insight into impaired neurodevelopment resulting from TH deficiency and a rich bioinformatics resource for developing a better understanding of TR binding.

Citation: Dong H, Yauk CL, Rowan-Carroll A, You S-H, Zoeller RT, et al. (2009) Identification of Thyroid Hormone Receptor Binding Sites and Target Genes Using ChIP-on-Chip in Developing Mouse Cerebellum. PLoS ONE 4(2): e4610. doi:10.1371/journal.pone.0004610

Editor: Patrick Callaerts, Katholieke Universiteit Leuven, Belgium

Received October 7, 2008; Accepted January 8, 2009; Published February 25, 2009

Copyright: © 2009 Dong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was founded by the Health Canada Genomics R&D fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: hongyan_dong@hc-sc.gc.ca

Introduction

Thyroid hormone (TH) is essential for brain development in humans and animals [1]. The neonatal period of human development is particularly well-studied in part because of the disorder known as congenital hypothyroidism (CH) [2]. CH occurs at a rate of approximately 1 in 3,500 live births [3], though this may be increasing [4]. CH infants do not present early specific clinical features; therefore, only 10% of CH infants were diagnosed within the first month, 35% within 3 months, 70% within the first year, and 100% only after age 3 [5,6] before neonatal screening for TH was implemented. The intellectual deficits resulting from this delayed diagnosis and treatment were profound. One meta-analysis found that the mean full-scale intelligence quotient (IQ) of 651 CH infants was 76 [7]. Moreover, the percentage of CH infants with an IQ above 85 was 78% when the diagnosis was made within 3 months of birth, 19% when it was made between 3 and 6 months, and 0% when diagnosed after 7 months of age [7,8]. Thus, TH plays a major role in brain development and thyroid dysfunction is a major cause of mental retardation. This is also particularly important because a large number of environmental contaminants may impact thyroid function and/or thyroid hormone action [9–12].

The molecular mechanisms by which TH impacts brain development are becoming better understood. In general, it is postulated that many of the effects of TH are mediated by their receptors (TRs) – nuclear proteins that directly regulate gene expression [13]. Likewise, the neurodevelopmental events affected by TH are also becoming better understood. For example, TH appears to regulate fate specification of early cortical neurons [14], migration of cortical [15] and cerebellar [16] neurons, synaptogenesis[17,18] and apoptosis [19,20]. However, the specific genes that are directly regulated by TH through the TRs, and which account for TH effects on specific developmental events, are poorly characterized. Moreover, we know little about the DNA regulatory elements through which TRs exert their actions on gene regulation [21].

Identification of direct targets of TH in the developing brain has proven difficult, but perhaps for predictable reasons. Specifically, we [19,22] and others [23,24] have attempted to identify TH-responsive genes in the developing brain using a variety of “functional genomics” approaches. All of these reports employed
an RNA-based approach. However, a significant theoretical weakness in this approach is that the cellular phenotype of the hypothyroid brain in development is significantly different from that of the euthyroid brain. For example, the hypothyroid brain has considerably more astrocytes and fewer oligodendrocytes in areas of white matter [25,26]. Therefore, it is likely that a large number of expressed sequences that differ in abundance when thyroid hormone levels are manipulated during development reflect differences in cellular phenotype at the time of sacrifice.

Considering the importance of TH to brain development and the challenge of identifying direct gene targets of TH action, we reasoned that chromatin immunoprecipitation combined with DNA microarray analysis (ChIP-on-chip) would be an effective approach to identify direct gene targets of TH. Moreover, we chose to focus on the neonatal (postnatal day (PND) 15) cerebellum because it is a well studied target of TH action in development [27]. Circulating TH levels reach a peak at PND 15 [28,29], the critical time point marked by the onset of active myelination and synapses refinement in Purkinje cells [25,30,31]. We employed custom DNA microarrays that contained probes covering 10 kb of genomic sequences flanking the transcription start site (TSS) of 5000 genes selected from our previous microarray studies and related literatures. The use of microarrays containing selected genes tends to limit the potential for false positives that would invariably occur with arrays containing the entire genome and increases the number of probes per gene, thus improving sensitivity and resolution. This study represents the first large-scale approach to identify direct gene targets of TH action in the developing brain.

**Results**

**Assessing specificity of polyclonal antibody and ChIP protocol**

The TRβ-1 antibody used for ChIP in the current study showed high specificity as indicated by Western blot analysis using GH3 cell extracts (Figure 1 A). A single band of 52 kDa was detected as expected. Immunoprecipitated (IP) DNA and total input (TI) DNA were amplified and evaluated by confirming the enrichment of the well-characterized TRE in the promoter of myelin basic protein (MBP) [32] by PCR before samples were hybridized to DNA microarrays. Figure 1 B shows clear enrichment of MBP-
TRE (relative to β-actin) in amplified ChIP DNA of all 5 cerebella of male mice at PND 15.

Identification of TRβ binding sites

Five cerebella of male mice, shown in Figure 1 B, were analysed using the Agilent custom promoter arrays that contained probes covering 10 kb of genomic sequences flanking the TSS of 5000 selected genes. Complete microarray data are available at MIAMEExpress (http://www.ebi.ac.uk/miamexp/cgi-bin/mx.cgi; accession number E-MEXP-1801). The genes identified with the Chip Analytics software as enriched in at least 3 samples are listed in Table 1, along with the genomic location of the binding sites, enrichment log ratio, and general biological function. As shown in Figure 2, approximately half of the binding sites were located in introns, while about 30% of them were located within 1 kb upstream of the TSS of their associated gene. Figure 3 shows examples of ChIP enrichment data for 4 representative genes. The plots show enrichment ratios along with chromosomal positions (NCBI build 34) in the mouse genome. Arrows indicate both the TSS and direction of transcription.

Validation of the binding sites with ChIP-PCR

In order to verify the robustness of binding sites found with ChIP-on-chip, we randomly selected and analyzed 13 binding sites for confirmation of their enrichment using PCR. β-actin was used as a negative control, and MBP-TRE was used as a positive control. Amplified TRβ-IP or IgG-IP DNAs along with TI-DNAs from 2 cerebella were pooled, with equal quantities of DNA from each sample, and used as template for PCR. Ten of the 13 genes were confirmed to be enriched with TRβ binding as shown in Figure 4. Of the 10 confirmed genes, CD44 and VLDLR have previously been reported as TH responsive genes [29,30]. In addition to the well-known TRE sequence in the promoter region of MBP, we also identified a second enrichment site in the first intron of Golli-MBP [31]. As 3 (Fign, CD81and Pax3) of 13 binding sites tested were not confirmed by PCR, these data suggest the analysis has false discovery rate of approximately 23% (3/13).

Expression of novel TH target genes in TH modulated animal models

Among the 10 ChIP-PCR validated genes, SMS (Spermine Synthase), LMO2 (Lim domain only 2) and GTFF3c1 (General Transcriptor Factor 3c1) were selected for further assessment of TH regulation using in vivo models; this selection was based on the paucity of literature regarding TH control of their expression. In addition, myelinated associated glycoprotein (MAG) was also selected for further analysis as it has been shown to be altered by TH status but no TRE has been described for this gene [32]. The expression of MBP was, again, used as a positive control for TH-induced gene regulation in the various animal models. Serum T4 levels in 6- to 8-week-old male mice at PND 15. Approximately half of these sites are located within introns, and 30% are located within 1 kb upstream of the TSS. Several of these genes are known direct targets of TH action (CD44, MBP and VLDLR), indicating that our strategy was capable of identifying known targets. In addition to confirming the classical TRE in the MBP promoter [34], we identified a novel TRE binding site well upstream of the classic MBP TSS, located within the first intron of an alternate transcript of this gene known as Golli-MBP [35]. Golli-MBP is expressed not only in myelin-forming cells, but also in neurons in the CNS and peripheral nervous system, and in macrophage and T-cells of the immune system [36,37]. Direct TR regulation of Golli-MBP indicates the important role of TH in myelination and migration of oligodendrocytes, in addition to its role in the immune system. These findings provide a first glimpse at the specific gene targets through which TH controls cerebellar histogenesis in the mouse.

We found that a large proportion (47%) of the TR binding sites are located within introns, suggesting that transcriptional control by TR could be exerted at sites downstream of the TSS. It has long been recognized that active TREs can reside within introns of TH responsive genes. The TH-regulated expression of GH is mediated through a TRE in the regulatory region upstream of the TSS [38] and a site with higher affinity for TR within the third intron of the gene [39]. Similarly, the expression of hepatic carnitine palmitoyltransferase-1 alpha, an enzyme involved in fatty acid metabolism, is regulated by TR action at a TRE located in the first intron [40]. Intronic locations of transcriptional regulatory sites appear to be common for a variety of nuclear receptors including the androgen receptor [41], glucocorticoid receptor

Characterization of TRβ binding region in promoter of MAG

As described above, the TRβ binding site in the promoter region of MAG was confirmed with both ChIP-on-Chip and ChIP-PCR. There were no obvious candidate TREs, based on the degenerate consensus sequence, across this binding region. To further characterize the TRE sequence in this region, we constructed a series of truncated MAG-promoter reporter plasmids (shown in Figure 6 A). The reporter system was validated by examining the effect of T3 treatment on transcriptional activity of the Growth Hormone (GH) TRE sequence cloned into the reporter vector. T3 induced GH transcriptional activity by 1.6-fold (Figure 6 B). T3 also increased transcriptional activity of a MAG-promoter reporter plasmid containing a fragment from 390 bp to the TSS, by 1.4-fold. Deletion of the 110 bp fragment from 390 to 280 bp resulted in a decrease in the basal transcription level; transcription activity was induced by only 1.2 fold with T3 treatment (Figure 6 C). These results indicate that the binding site spanning a region of 110 bp (390 to −280) may include the potential TREs.

Discussion

This is the first report of a relatively large-scale approach to identify direct TH gene targets in the developing mouse brain. Using ChIP-on-chip approach, we identified TRβ binding fragments corresponding to 91 genes in the cerebellum of male mice at PND 15. Approximately half of these sites are located within introns, and 30% are located within 1 kb upstream of the TSS. Several of these genes are known direct targets of TH action (CD44, MBP and VLDLR), indicating that our strategy was capable of identifying known targets. In addition to confirming the classical TRE in the MBP promoter [34], we identified a novel TR binding site well upstream of the classic MBP TSS, located within the first intron of an alternate transcript of this gene known as Golli-MBP [35]. Golli-MBP is expressed not only in myelin-forming cells, but also in neurons in the CNS and peripheral nervous system, and in macrophage and T-cells of the immune system [36,37]. Direct TR regulation of Golli-MBP indicates the important role of TH in myelination and migration of oligodendrocytes, in addition to its role in the immune system. These findings provide a first glimpse at the specific gene targets through which TH controls cerebellar histogenesis in the mouse.
| Acc. No. | Gene Symbol | Probe Location | Enrichment Log ratio | Median | Rep1 | Rep2 | Rep3 | Rep4 | Rep5 |
|----------|-------------|----------------|----------------------|--------|------|------|------|------|------|
| **Apoptosis** | | | | | | | | | |
| NM_028133 | Egln3 | intron | 2.7 | 1.59 | 1.77 | 2.28 | 1.63 | 1.77 | |
| NM_178931 | Tnfrsf14 | intron | 1.92 | 1.8 | 2.45 | 2.01 | 1.36 | 1.92 | |
| NM_010589 | Jak3 | 2.2 kb | 5 | 4.32 | 3.22 | 1.7 | 2.02 | 1.32 | 2.02 |
| NM_008353 | Il12rb1 | 6.7 kb | 5 | 2.88 | 1.93 | 2.17 | 2.1 | 1.76 | 2.1 |
| NM_007466 | Api5 | intron | 2.68 | 4.52 | 0.29 | 2.27 | 0.74 | 2.27 | |
| NM_175445 | Rassf2 | 0.7 kb | 5 | 1.58 | 2.57 | 2.76 | 2.46 | 2.2 | 2.46 |
| NM_013929 | Siva | 0.7 kb | 5 | 2.24 | 2.7 | 2.52 | 3.06 | 2.91 | 2.7 |
| NM_008353 | Il12rb1 | 6.7 kb | 5 | 2.88 | 1.93 | 2.17 | 2.1 | 1.76 | 2.1 |
| NM_007466 | Api5 | intron | 2.68 | 4.52 | 0.29 | 2.27 | 0.74 | 2.27 | |
| NM_175445 | Rassf2 | 0.7 kb | 5 | 1.58 | 2.57 | 2.76 | 2.46 | 2.2 | 2.46 |
| NM_013929 | Siva | 0.7 kb | 5 | 2.24 | 2.7 | 2.52 | 3.06 | 2.91 | 2.7 |
| NM_008353 | Il12rb1 | 6.7 kb | 5 | 2.88 | 1.93 | 2.17 | 2.1 | 1.76 | 2.1 |
| **Cell cycle** | | | | | | | | | |
| NM_133655 | Cdk1 | intron | 1.56 | 1.33 | 2.2 | 1.87 | 1.37 | 1.56 | |
| NM_023117 | Cdc25b | 0.1 kb | 5 | 1.44 | 3.03 | 1.73 | 1.7 | 1.96 | 1.73 |
| NM_030241 | Setd8 | 0.2 kb | 5 | 2.53 | 4.06 | 1.44 | 1.89 | 1.12 | 1.89 |
| **Teeth or bone development** | | | | | | | | | |
| BC005460 | Ncl | 0.4 kb | 5 | 1.95 | 1.98 | 1.38 | 1.26 | 1.78 | 1.78 |
| NM_010514 | Igf2 | intron | 3.46 | 2.83 | 1.39 | 1.91 | 1.53 | 1.91 | |
| NM_008275 | Hoxd13 | 1.2 kb | 5 | 2.26 | 2.73 | 2.3 | 6.33 | 2.42 | 2.42 |
| NM_145925 | Pttg1p | intron | 3.66 | 3.14 | 3.39 | 3.93 | 0.87 | 3.93 | 3.39 |
| **RNA or DNA process** | | | | | | | | | |
| AK077829 | Rad51ap1 | intron | 5.02 | 2.34 | 4.68 | 2.72 | 2.48 | 2.72 | |
| AK077107 | Frg1 | 0.2 kb | 5 | 1.92 | 1.48 | 3.5 | 2.56 | 1.69 | 1.92 |
| NM_182650 | Hnmpa2b1 | 0.5 kb | 5 | 3.13 | 4.89 | 5.08 | 1.66 | 2.03 | 3.13 |
| **Metabolism** | | | | | | | | | |
| NM_007823 | Cyp4b1 | intron | 1.35 | 2.02 | 1.51 | 2 | 1.67 | 1.67 | |
| NM_011977 | S1c27a1 | intron | 2.45 | 2.19 | 0.99 | 1.67 | 1.54 | 1.67 | |
| NM_025578 | Mrps25 | 0.2 kb | 5 | 3.64 | 1.74 | 2.86 | 1.37 | 1.75 | 1.75 |
| NM_153803 | Glb112 | intron | 7.42 | 1.29 | 4.57 | 1.93 | 0.86 | 1.93 | |
| NM_027868 | S1c41a3 | intron | 2.08 | 2.19 | 2.54 | 2.07 | 1.66 | 2.08 | |
| NM_008131 | Glul | intron | 1.85 | 2.67 | 2.14 | 2.14 | 2.11 | 2.14 | |
| NM_173311 | Zfp513 | intron | 2.14 | 1.95 | 1.85 | 3.13 | 2.57 | 2.14 | |
| NM_010361 | Gstt2 | 3.4 kb | 5 | 1.73 | 4.32 | 1.71 | 2.44 | 2.31 | 2.31 |
| NM_026796 | Smyd2 | intron | 2.06 | 7.09 | 2.4 | 2.79 | 1.29 | 2.4 |
| NM_011376 | Sim1 | 1.5 kb | 5 | 1.9 | 1.51 | 5.08 | 3.44 | 2.45 | 2.45 |
| NM_025802 | Pnpia2 | intron | 5.57 | 3.97 | 2.47 | 2.28 | 1.06 | 2.47 | |
| NM_008972 | Ptma | intron | 2.89 | 3.74 | 2.47 | 2.26 | 2.02 | 2.47 | |
| NM_146188 | Kctd15 | 0.8 kb | 5 | 3.13 | 3.78 | 2.54 | 2.18 | 1.77 | 2.54 |
| NM_008673 | Nat1 | 6.2 kb | 5 | 2.55 | 3.51 | 2.65 | 1.9 | 1.53 | 2.55 |
| NM_020013 | Fgfl2 | intron | 2.09 | 2.56 | 5.73 | 2.78 | 2.37 | 2.56 | |
| NM_023122 | Gpmb6 | intron | 5.29 | 4.33 | 2.9 | 1.1 | 2.77 | 2.8 | |
| NM_019652 | ASNA1 | intron | 4.7 | 5.65 | 2.84 | 2.3 | 2.41 | 2.84 | |
| NM_011506 | Sucld2 | intron | 4.45 | 2.93 | 5.47 | 2.52 | 1.56 | 2.93 | |
| NM_025286 | S1c31a2 | intron | 3.29 | 2.87 | 1.93 | 4.71 | 3.66 | 3.29 | |
| NM_011969 | Psma7 | intron | 2.84 | 3.45 | 3.3 | 3.27 | 3.38 | 3.3 | |
| NM_007945 | Eps8 | 0.6 kb | 5 | 2.82 | 3.95 | 4.55 | 2.75 | 4.55 | 3.95 | |
| **Nerve development** | | | | | | | | | |
| NM_027180 | Centd2 | 3.8 kb | 5 | 3.98 | 1.9 | 1.3 | 1.58 | 0.86 | 1.58 | |
| Acc. No. | Gene Symbol | Probe Location | Enrichment Log ratio | Median |
|---------|-------------|----------------|----------------------|--------|
|         |             |                | Rep1 | Rep2 | Rep3 | Rep4 | Rep5 |
| NM_010419 | Hes5 | 7.8 kb 5’ | 1.57 | 1.68 | 2.17 | 1.77 | 1.82 | 1.77 |
| NM_008500 | Lhx6 | 0.1 kb 5’ | 5.12 | 5.26 | 1.83 | 1.82 | 1.26 | 1.83 |
| NM_008630 | Mt2 | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_009851 | CD44 intron | 1.91 | 2.1 | 1.73 | 2.08 | 1.92 | 1.92 |
| AF113001 | Ncor2 | 0.7 kb 5’ | 1.34 | 3.35 | 4.19 | 1.92 | 1.54 | 1.92 |
| NM_207682 | Kif1b | 0.5 kb 5’ | 1.16 | 1.96 | 2.89 | 3.4 | 1.17 | 1.96 |
| NM_010758 | Mag | 0.4 kb 5’ | 1.64 | 1.86 | 2.64 | 2.41 | 2.02 | 2.41 |
| NM_009800 | Lhx2 | 0.6 kb 5’ | 3.29 | 2.52 | 2.17 | 2.1 | 1.28 | 2.17 |
| NM_001029873 | Unc13a | 4.5 kb 5’ | 5.12 | 5.26 | 1.83 | 1.82 | 1.26 | 1.83 |
| NM_021716 | Fign | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010777 | Mt2 | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010710 | Lhx2 | 0.6 kb 5’ | 3.29 | 2.52 | 2.17 | 2.1 | 1.28 | 2.17 |
| NM_009800 | Car11 | 0.2 kb 3’ | 1.27 | 2.18 | 5.11 | 3.25 | 1.5 | 2.18 |
| NM_009849 | Ncor2 | 0.7 kb 5’ | 1.34 | 3.35 | 4.19 | 1.92 | 1.54 | 1.92 |
| NM_021716 | Fign | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010777 | Mt2 | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010710 | Lhx2 | 0.6 kb 5’ | 3.29 | 2.52 | 2.17 | 2.1 | 1.28 | 2.17 |
| NM_001029873 | Unc13a | 4.5 kb 5’ | 5.12 | 5.26 | 1.83 | 1.82 | 1.26 | 1.83 |
| NM_021716 | Fign | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010777 | Mt2 | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010710 | Lhx2 | 0.6 kb 5’ | 3.29 | 2.52 | 2.17 | 2.1 | 1.28 | 2.17 |
| NM_009800 | Car11 | 0.2 kb 3’ | 1.27 | 2.18 | 5.11 | 3.25 | 1.5 | 2.18 |
| NM_009849 | Ncor2 | 0.7 kb 5’ | 1.34 | 3.35 | 4.19 | 1.92 | 1.54 | 1.92 |
| NM_021716 | Fign | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010777 | Mt2 | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010710 | Lhx2 | 0.6 kb 5’ | 3.29 | 2.52 | 2.17 | 2.1 | 1.28 | 2.17 |
| NM_009800 | Car11 | 0.2 kb 3’ | 1.27 | 2.18 | 5.11 | 3.25 | 1.5 | 2.18 |
| NM_009849 | Ncor2 | 0.7 kb 5’ | 1.34 | 3.35 | 4.19 | 1.92 | 1.54 | 1.92 |
| NM_021716 | Fign | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010777 | Mt2 | 0.8 kb 5’ | 1.85 | 2.85 | 1.99 | 1.40 | 0.85 | 1.85 |
| NM_010710 | Lhx2 | 0.6 kb 5’ | 3.29 | 2.52 | 2.17 | 2.1 | 1.28 | 2.17 |
| NM_009800 | Car11 | 0.2 kb 3’ | 1.27 | 2.18 | 5.11 | 3.25 | 1.5 | 2.18 |
| NM_009849 | Ncor2 | 0.7 kb 5’ | 1.34 | 3.35 | 4.19 | 1.92 | 1.54 | 1.92 |
Table 1. cont.

| Acc. No. | Gene Symbol | Probe Location | Enrichment Log ratio | Median |
|----------|-------------|----------------|----------------------|--------|
|          |             |                | Rep1  Rep2 Rep3 Rep4 Rep5 |
| BC085130 | MKIAA4027   | intron         | 4.26  2.01 2.16 1.57 0.63 2.01 |
| NM_028696| Obfc2a      | intron         | 4.03  2.44 2.3 2.37 1.8 2.37 |
| NM_026626| Efcab2      | intron         | 2.31  3.2 3.98 2.49 1.88 2.49 |
| NM_001101503| Riken | 1.5 kb 3'     | 2.93  3.14 2.69 3.93 1.59 2.93 |
| NM_144558| BIVM        | 0.8 kb 5'      | 1.65  2.03 3.07 3.12 3.74 3.07 |

Figure 2. Distribution of genomic locations of binding sites of 91 genes. The mid point of each probe was used to calculate the distance to the closest gene.
doi:10.1371/journal.pone.0004610.g002

Figure 3. Examples of TRb binding activities identified with ChIP-on-chip. The plots show enrichment ratios for all probes within a genomic region (IP versus TI DNA). Chromosomal positions are from NCBI build 34 of the mouse genome. The start and direction of transcription are noted by arrows. Black bars on the X axis indicate the fragments whose enrichment was confirmed with PCR.
doi:10.1371/journal.pone.0004610.g003
TR binding sites identified with ChIP-on-chip were analyzed independently with ChIP-PCR for 13 randomly selected genes. Ten of these sites were confirmed as enriched by TRβ ChIP, suggesting a false positive rate of approximately 23% for our approach. ChIP-on-chip is a novel method to study chromatin–DNA interactions over the entire genome. Our results are not unusual given that previous data from ChIP-on-chip studies have reported false positive rates as high as 30% [47]. There are a number of confounding variables, including purity of ChIP DNA, amplification methods and resolution of probes for each gene. It is also probable that the list of enriched genes identified by ChIP-on-chip is highly dependent on the algorithm applied (normalization, statistics to identify enriched regions, criteria for calling a site significant, etc.) which may influence the rate of false positives and false negatives.

Identified as one of novel targets of TH regulation, SMS is essential for transforming spermidine to spermine, which are ubiquitous cellular components that play critical roles in cellular physiology [48]. Polyamines are required for numerous cellular processes including transcription, translation and modulation of ion channel activities [49,50]. Deficiency of SMS in mice is associated with deafness, inner ear abnormalities, and hyperactivity, while congenital deficiency in humans is associated with mental retardation and cerebellar abnormalities [51]. All of these phenotypes are common manifestations of developmental hypothyroidism [52]. In the current study we identified TR binding sites in the promoter region of SMS. Moreover, TH positively regulated the expression of SMS in both mouse models of TH disruption. Microarray analyses of cerebellum transcript levels in mice or rats treated with a low concentration of PTU showed that SMS expression was reduced in hypothyroid mice of both sexes, but only in male hypothyroid rats (in preparation). Therefore, down-regulation of SMS, causing decreased production of polyamines, may be one mechanism that leads to neurodevelopmental aberrations in the offspring of hypothyroid dams. More work is required to investigate this pathway and its response to TH in the brain.

Among the other novel TH target genes selected for further analysis, LMO2 is a member of a family of genes encoding Lim-only proteins, which are speculated to affect the development of the mouse CNS because of their high expression in this region [53–55]. Using both ChIP-on-chip and ChIP-PCR, we found that TR bound to a LMO2 intron, and our results suggest that LMO2 expression is regulated by TH in our animal models. GTF3c1 is a transcription factor required for the regulation of genes transcribed by RNA polymerase III [56]. Our results indicate a TR binding site in the first intron of this gene and that the expression of GTF3c1 is upregulated in the cerebellum of hypothyroid animals with TH replacement (Figure 5). However, the reduced expression was found in hypothyroid animals induced by PTU, but not in animals induced by MMI/perchlorate. This suggests that factors other than TH may prevent the reduction in GTF3c1 expression. A recent study examining hepatic genome-wide expression in wild type and TR knock-out mice treated with TH or goitrogen found that, like GTF3c1, roughly half of all genes that showed positive regulation by TH excess, exhibited no response to TH deficiency [57]. Although that study did not attempt to determine the presence of genomic TR binding sites that could potentially regulate the expression of these genes, the results suggest that the pattern of response of GTF3c1 expression in the
The cerebella of TH-manipulated animals may not be uncommon for TH regulated genes.

MAG is a quantitatively minor component of isolated myelin that functions in glia-axon interactions [58]. The abnormal expression of MAG in hypo/hyperthyroidism has previously been reported in several studies [59–61], but there is little information on how its expression is directly affected by TH. The current study shows that TRβ binds in the region between −280 to −390 bp, which significantly influences the transcription activity. A search using an internet based tool to identify TREs based on classical descriptions (TESS: Transcription Element Search System [62]: located at http://www.cbil.upenn.edu/cgi-bin/tess/tess;) failed to identify any of the classic TRE forms (DR4, DR6, palindromic form or inverted palindrome), suggesting that the sequence of the binding site is novel. We found a half TRE (AGGTCA) in this region, but alteration of this sequence to AGATCA by site-directed mutagenesis had no effect on the transcriptional activity in vitro (data not shown). This suggests that TRβ may not bind to the half TRE and that this specific sequence has no functional significance. The expression of MAG in our animal models is correlated with TH level suggesting that the presence of a TR binding site in the regulatory region of the gene is genuine. Further analyses will be needed to characterize the nature and sequence of the TR regulatory element in this gene, but current findings indicate that not all TREs will conform to variations of the classic forms.

In conclusion, we have identified TR binding sites associated with 91 genes in the developing mouse cerebellum. Binding sites may be located in different genomic contexts (both upstream and downstream of genes, and in introns) and may not adhere to conventional sequence models. As TR binding suggests the presence of consensus thyroid regulatory elements and, hence, direct TH regulation of these genes, the current study provides support for the role of products of these genes in thyroid hormone-directed neurodevelopment.

Figure 5. The expression of novel thyroid responsive genes in hypothyroid or hyperthyroid mouse models. A. MMI/perchlorate induced hypothyroid, hyperthyroid or hypothyroid/replacement animal models. B. PTU induced hypothyroid animal models. RT-PCR was performed with RNA extracted from cerebellum on PND15 (n = 5). * Significantly different from control (p<0.05).

doi:10.1371/journal.pone.0004610.g005
A

![Graph showing enrichment ratio with probes and TSS](image)

- Plasmid 1, TSS to -180bp
- Plasmid 2, TSS to -280bp, include probe 1
- Plasmid 3, TSS to -390bp, include probe 2

B

![Bar chart showing relative luciferase units](image)

- pGL4.10
- GH

C

![Chart showing luciferase activity with T3 and PBS](image)

- Plasmid 3: 1.41 ± 0.19
- Plasmid 2: 1.22 ± 0.10
- Plasmid 1: 1.20 ± 0.11
- pGL4.10: 1.02 ± 0.01

Relative Luciferase Unit
Figure 6. The transcriptional activity of the MAG promoter examined with the luciferase reporter assay. A. The location of the 3 truncated fragments used to build the reporter constructs. The PCR-confirmed ChIP enriched fragment is indicated by the black bar. The TSS and direction is indicated with an arrow. B and C. Transcriptional activity of GH reporter construct or MAG promoter reporter constructs induced by TH. The reporter constructs and empty vector were co-transfected into GH3 cells with pRL-TK (as a transfection efficiency control). T3 (10^{-8} M) was added after 24 hrs. Firefly luciferase expression was normalized to renilla luciferase from the pRL-TK plasmid. Values are mean ± S.E. (n = 3). *indicates p<0.05.

doi:10.1371/journal.pone.0004610.g006

Materials and Methods

Animals and tissues collection

ChIP-on-chip. All animal handling procedures adhered to the Canadian Council on Animal Care guidelines and were approved by the Health Canada Animal Care Committee prior to the initiation of the study. Nulliparous, sexually mature C57BL/6 mice were purchased from Charles River (St. Constant, QC, Canada) and were housed individually (males) or in pairs (females) in hanging polycarbonate cages under a 12:12 hrs light-dark cycle at 23°C with food (Purina rodent chow 5010; Ralston-Purina, MO) and water available 

plug, as an indication of pregnancy. Plug positive females were examined within 1 hr of light cycle for the presence of a vaginal plug as an indication of pregnancy. Plug positive females were weighed and transferred to separate cages, where they were housed singly and weighed 10 days post coitus to confirm pregnancy. Dams were allowed to litter naturally (day of birth = PND 1) and numbers of pups per litter were not adjusted. On PND 15, pups were sacrificed by decapitation and cerebellum was removed, immediately frozen in liquid nitrogen and stored at −80°C.

PTU hypothyroid model. Pregnant C57BL/6 mice were supplied 

with water containing diet with cherry Kool-aid (Kraft Inc., ON, Canada) with or without 0.1% PTU (Sigma-Aldrich, Oakville, ON, Canada) from gestation day 13 to PND 15. On PND 15, 5 male pups from different litters were sacrificed by decapitation and cerebellum was collected and stored at −80°C. At least one littermate of the same sex was exsanguinated under isofluorane anesthesia and serum retained for T4 analysis.

MMI hypo/hyperthyroid models. Twenty-eight pregnant C57BL/6 mice were divided randomly into 4 groups: control, hypothyroid, hypothyroid/replacement and hyperthyroid. On PND 5 all dams were supplied with drinking water containing sucrose starting at 1% and increasing to 2% on PND 9. Dams and their litters in the hypothyroid and hypothyroid/ replacement groups were rendered hypothyroid for 5 days by providing drinking water containing 0.05% MMI. 1% sodium perchlorate and 2% sucrose water starting on PND 12. On PND 15 all pups received i.p. injections of saline containing 2 μM NaOH (Control and hypothyroid); T4/T3 at 50 μg/5.0 μg/100 g B.W. (hyperthyroid); or T4/T3 at 25 μg/2.5 μg/100 g B.W. (hypothyroid/replacement). Pups were sacrificed by decapitation exactly 4 hrs post injection. Serum was collected from trunk blood and retained for T4 analysis. The cerebellum was rapidly dissected, frozen in liquid nitrogen and stored at −80°C.

Chromatin immunoprecipitation (ChIP) and DNA microarrays (chip)

ChIP was performed using EZ ChIP kits (Millipore Corporation, Danvers, MA) according to the manufacturer’s instructions. Briefly, cerebellum from PND 15 mouse was homogenized, with a hand-held homogenizer, in PBS containing broad-spectrum protease inhibitors and was then cross-linked with 1% formaldehyde. Nuclei were collected by adding lysis buffer after cross-linkage was stopped with glycine. To ensure that DNA fragments ranged from 300 to 600 bp, the nuclear solution was sonicated, using a Fisher 60 Sonic Dismembranator (Thermo Fisher Scientific, Nepean, ON, Canada), in an ice bath with 5× 30 sec bursts at 12% power, each separated by 30 sec periods. Six percent (about 100 μl) of the sonicated solution was store at −20°C as TI, while the remainder was incubated with anti-TRβ polyclonal antibody (PA1-213, cloneTRb-62, Affinity Bioreagents, Golden, CO) overnight with agitation at 4°C (for ChIP-PCR, half of the remainder was incubated with anti-TRβ polyclonal antibody, the other half was incubated with normal rabbit IgG (Millipore Corporation, Danvers, MA)). Antibody-bound chromatin was precipitated with protein G conjugated agarose beads, washed with gradient stringent buffers, and eluted with elution buffer as per the manufacturer’s instructions. The eluted solution, as well as the stored TI, was incubated at 65°C overnight to reverse cross-links. IP DNA and TI DNA were then purified by treatment with RNase, proteinase K and multiple phenol: chloroform: isomyl alcohol (25:24:1) extractions. Equivalent amounts of IP DNA and TI DNA were amplified in parallel, using a random primer method with GenomePlex Complete Whole Genome Amplification Kit (Sigma-Aldrich, Oakville, ON, Canada), according to the manufacturer’s instructions (15 cycles).

Genomic regions enriched by ChIP were identified using Agilent custom microarrays (Agilent Technologies, Mississauga, ON, Canada) containing representative sequences from 5000 mouse genes selected as potential TH-regulated candidates based on our previous studies [19,63] or from the literatures. The full list of genes is available upon request. The microarrays were prepared such that each array was composed of two slides of 44,000 spots each. Promoter oligo probes (50–60 mers) complementary to genomic sequences ranged from −8 kb upstream to 2 kb downstream of the TSS of each gene with 200 bp between adjacent probes.

Amplified IP or TI DNA samples (2 μg) was labelled with Cy5-dUTP or Cy3-dUTP (Perkin Elmer Life Sciences, Woodbridge, ON, Canada), respectively, using CGH kits (Invitrogen, Burlington, ON, Canada). Labelled DNAs (5 μg each) were hybridized with custom promoter microarrays for 40 hrs at 65°C, then washed and dried according to the manufacturer’s instructions.

Hybridization images were obtained using an Agilent DNA microarray scanner and intensity data was extracted using Feature Extraction software (Agilent Technologies). Genomic regions enriched by ChIP were identified with a peak detection algorithm using Chip Analytics 1.3 software, according to the manufacturer’s instructions (Agilent Technologies). Intensity data were normalized with blank subtraction followed by intra-array Lowess normalization, while the Whitehead Error Model v1.0 was used to calculate confidence values for each spot on each array. The Whitehead per-array neighbourhood model v1.0 was used to identify the bound regions. Criteria for identification of a positive probe were: 1) P-value for probe spots (probe and its two immediate neighbours) was less than 0.001; and 2) two of three probes in a probe set had a single probe P-value less than 0.005, or, the center probe in the probe set had a single probe P-value less than 0.001 and one of the flanking probes had a single P-value less than 0.1.

ChIP-PCR. Primers targeting the enriched regions identified with ChIP-on-chip analysis were designed using BeaconDesigner
2.0 Software (Premier Biosoft, Palo Alto, CA). PCRs were performed using AmpliTaq (Perkin Elmer) with amplified TRβ-IP, IgG-IP or T3 DNA pooled of 2 independent samples as templates. Primer sequences are indicated in Table S2.

Expression RT-PCR. Total RNA was extracted from cerebellum using Trizol, and reverse transcribed into cDNA using SuperScript III (Invitrogen). Quantitative PCR was performed with an iCycler IQ real-time detection system (Bio-Rad Laboratories, Mississauga, ON, Canada) using SYBR-Green. Primers were designed using Beacon Designer 2.0, and sequences can be found in Table S3. Gene expression levels were normalized to Hprt, which was found to be stable using the DNA microarray (data not shown). PCR efficiency was examined using the standard curve for each gene. The primer specificity was determined by the melting curve for each amplicon.

Reporter plasmid construction. Mouse MAG luciferase reporter plasmids 1–3 were constructed by cloning PCR-derived fragments (MAG nucleotides +14 to −180, −280, −390) into the luciferase vector, PGL4.10 (Promega, Madison, WI, USA). PCRs were performed using primers containing XhoI and BglII sites with mouse genomic DNA as template. PCR fragments were then subcloned into XhoI/BglII sites of pGL4.10 and the constructed sequences were confirmed by restriction enzyme mapping and sequencing.

Cell culture, transfection, and reporter assay. Twenty-four hrs before transfection, GH3 cells (2 × 10^5) were seeded in each well of 6-well plates with F12 medium containing 10% dextran-coated charcoal-treated FBS. Each luciferase reporter plasmid construct (1.02 μg) was co-transfected with 0.03 μg of pRL-TK (Promega) into GH3 cells using 3 μl of FUGENE 6 (Agilent). Twenty four hrs post-transfection, T3 was added to a final concentration of 10⁻¹⁰ M. Cells were harvested 24 hrs after T3 addition, and then firefly and renilla luciferase activities were determined in cell lysates using a Veritas luminometer with the Dual-luciferase reporter assay system (Promega). Firefly luciferase activity was normalized to renilla luciferase activity to correct for transfection efficiency and the reporter gene expression presented as relative luciferase units (RLU). Each incubation was performed in duplicate and experiments were repeated 3 times.

**Western blots.** Lysis buffer (200 μl) was added to 1 × 10⁶ GH3 cells and 50 μg protein was loaded in each lane and separated on a 10% SDS-PAGE gels, then were transferred to nitrocellulose membranes at 100 V for 1 hr. Membranes were probed with anti-TRβ polyclonal antibody (Affinity Bioreagents; 3 μg/ml) overnight and HRP-conjugated goat anti-rabbit secondary antibody (Santa Cruz Biotechnology, CA; 1:1000) for 2 hrs. Signals were detected using an ECL Plus kit (GE Healthcare Bio-Science Inc. Baie d’Urfé, QC, Canada).

**Statistical analysis.** RT-PCR gene expression and luciferase activity data are expressed as mean±S.E. Significant differences compared to control were determined using a 2-tailed Student’s t-test and were deemed significant if P<0.05.

**Supporting Information**

Table S1 ChIP PCR primers

| Found at: doit:10.1371/journal.pone.0004610.s001 | 0.03 MB DOC |

Table S2 Gene expression PCR primers

| Found at: doit:10.1371/journal.pone.0004610.s002 | 0.03 MB DOC |

Table S3 Serum T4 of mouse pups from in vivo TH modulation studies

| Found at: doit:10.1371/journal.pone.0004610.s003 | 0.03 MB DOC |

**Acknowledgments**

We thank Drs. Guillaume Pelletier and Kelly Jackson (all from Health Canada) for helpful comments on the manuscript.

**Author Contributions**

Conceived and designed the experiments: HD CY TZ IL MGW. Performed the experiments: HD ARC SHY. Analyzed the data: HD MGW. Contributed reagents/materials/analysis tools: MGW. Wrote the paper: HD CY TZ MGW.

**References**

1. Bernal J (2007) Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab 3: 249–259.
2. Zoeller RT, Rovee J (2004) Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. J Neuroendocrinol 16: 809–818.
3. Delange F (1997) Neonatal screening for congenital hypothyroidism: results and perspectives. Horm Res 48: 51–61.
4. Harris KB, Pass KA (2007) Increase in congenital hypothyroidism in New York State and in the United States. Mol Genet Metab 91: 268–277.
5. Ahn J, Hagenfeldt L, Larsson A, Lundberg K (1994) Incidence of congenital hypothyroidism: retrospective study of neonatal laboratory screening versus clinical symptoms as indicators leading to diagnosis. Br Med J 309: 1171–1175.
6. Jacobsen BB, Brændt NJ (1981) Congenital hypothyroidism in Denmark: Incidence, types of thyroid disorders and age at onset of therapy in children: 1970–1975. Arch Dis Child 56: 134–136.
7. Klein R (1980) History of congenital hypothyroidism. In: Burrow GN, Dussault BH, eds. Neonatal Thyroid Screening. New York: Raven Press. pp 51–59.
8. Klein RJ, Mitchell ME (1996) Neonatal Screening for Hypothyroidism. In: Braverman LE, Utiger RD, eds. The Thyroid: A Fundamental and Clinical Text. Seventh ed. Philadelphia: Lippincott-Raven. pp 891–908.
9. Blount BC, Pidde JL, Ostereik JJ, Valentin-Blaum I, Caldwell KL (2006) Urinary perchlorate and thyroid hormone levels in adolescent and adult men and women living in the United States. Environ Health Perspect 114: 1863–1871.
10. Bruckner-Davis F (1998) Effects of environmental synthetic chemicals on thyroid hormone. Thyroid 8: 827–856.
11. Howeshead KL (2002) A model of the development of the brain as a construct of the thyroid system. Environ Health Perspect 110 Suppl 3: 337–348.
12. Zoeller RT (2007) Environmental chemicals impacting the thyroid: targets and consequences. Thyroid 17: 811–817.
13. Bassett JH, Harvey CB, Williams GR (2003) Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 213: 1–11.
14. Bansal R, You SH, Herzig CT, Zoeller RT (2005) Maternal thyroid hormone increases HES expression in the fetal rat brain: An effect mimicked by exposure to a mixture of polychlorinated biphenyls (PCBs). Brain Res Dev Brain Res 156: 13–22.
15. Auso E, Lavado-Autrnic R, Cuevas E, Escobar Del Rey F, Morreale De Escobar G, et al. (2004) A moderate and transient deficiency of maternal thyroid function at the beginning of fetal neocorticosgenesis alters neuronal migration. Endocrinology 145: 4037–4047.
16. Morte B, Manzano J, Scanlan T, Yenstrom B, Bernal J (2002) Deletion of the thyroid hormone receptor alpha 1 prevents the structural alterations of the cerebellum induced by hypothyroidism. Proc Natl Acad Sci U S A 99: 3895–3899.
17. Nicholson JL, Altman J (1972) Synaptogenesis in the rat cerebellum: effects of early hypo- and hypothyroidism. Science 176: 530–532.
18. Rami A, Rabie A (1990) Delayed synaptogenesis in the dentate gyrus of the thyroid-deficient developing rat. Dev Neurosci 12: 398–405.
19. Dong H, Wade M, Williams A, Lee A, Douglas GR, et al. (2005) Molecular insight into the effects of hypothyroidism on the developing cerebellum. Biochem Biophys Res Commun 330: 1182–1193.
20. Xiao Q, Nikodem VM (1998) Apoptosis in the developing cerebellum of the thyroid hormone-deficient rat. Brain Res Dev Brain Res 114: 1863–1871.
21. Yen PM (2005) Thyroid hormone action: genomic and nongenomic actions of thyroid hormones. In: Braverman LE, Utiger RD, eds. The Thyroid: A Fundamental and Clinical Text. 9 ed. Philadelphia: Lippincott Williams & Wilkins. pp 133–130.
22. Dowling AL, Martz GU, Leonard JL, Zoeller RT (2008) Acute changes in maternal thyroid hormone induce rapid and transient changes in gene expression in fetal rat brain. J Neurosci 28: 2253–2265.

23. Munoz A, Rodriguez-Pena A, Perez-Castillo A, Ferreiro B, Sutcliffe JG, et al. (1993) Structure and developmental regulation of Golli-mbp, a 105-kilobase basic protein gene. J Neurochem 59: 2318–2323.

24. Sharlin DS, Bansal R, Zoeller RT (2006) Polychlorinated biphenyls exert selective effects on cellular composition of white matter in a manner inconsistent with thyroid hormone insufficiency. Endocrinology 147: 486–490.

25. Crofton KM (2008) Thyroid disrupting chemicals: mechanisms and mixtures. Int J Androl 31: 209–223.

26. Porterfield SP, Hendrich CE (1993) The role of thyroid hormones in prenatal and neonatal neurological development-current perspectives. Endocr Rev 14: 94–106.

27. Quarles RH (2007) Myelin-associated glycoprotein (MAG): past, present and beyond. J Neurosci 27: 12690–12699.

28. Haas MJ, Mreyoud A, Fishman M, Mooradian AD (2004) Microarray analysis of thyroid hormone-induced changes in mRNA expression in the adult rat brain. J Biol Chem 279: 5549–5559.

29. Schug J (2008) Using TESS to predict transcription factor binding sites in DNA sequences. Curr Protoc Bioinformatics Chapter 2: Unit 2.6.

30. Reiter RJ, Fernandez-Turiel L, Vieweg W (1991) Effects of neonatal hypothyroidism on rat brain gene expression. Mol Endocrinol 5: 273–280.

31. Kakizawa S, Yamasaki M, Watanabe M, Kano M (2000) Critical period for thyroid hormone action in the rat brain. J Neurosci 20: 2255–2265.

32. Farsetti A, Desvergne B, Hallenbeck P, Robbins J, Nikodem VM (1992) Sequence and expression suggests multiple roles in mouse development. J Mol Biol 226: 279–283.

33. Yen PM, Feng X, Flamant F, Chen Y, Walker RL, et al. (2003) Effects of ligand and thyroid hormone receptor isoforms on hepatic gene expression profiles of thyroid hormone receptor knockout mice. EMBO Rep 4: 381–387.

34. Boettcher EP, Kasavettis GA (2001) The RNA polymerase III transcription apparatus. J Mol Biol 310: 1–26.

35. Foroni L, Boehm T, Spillantini MG, Sofroniew MV, Surani MA, Rabbits TH (1991) Developmentally regulated and tissue specific expression of mRNAs encoding the two alternative forms of the LIM domain oncogene rhomboid: evidence for thymus expression. Oncogene 6: 695–703.

36. Wang X, Kegoichi Y, McCloskey DE, Nelson P, Pegg AE (2004) Spermine synthesis is required for normal viability, growth, and fertility in the mouse. J Biol Chem 279: 51370–51375.

37. Crofton KM (2008) Thyroid disrupting chemicals: mechanisms and mixtures. Int J Androl 31: 209–223.

38. Sharlin DS, Tighe D, Gilbert ME, Zoeller RT (2008) The balance between oligodendrocyte and astrocyte production in major white matter tracts is linearly related to serum total thyroxine. Endocrinology 149: 2527–2536.

39. Koenig JI (1989) Pituitary gland: neuropeptides, neurotransmitters and growth factors. Toxicol Pathol 17: 256–265.

40. Jackson-Hayes L, Song S, Lavrentyev EN, Jansen MS, Hillgartner FB, et al. (2007) The gene encoding the Asyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. J Biol Chem 272: 26281–26290.

41. Thompson CC (1996) Thyroid hormone-responsive genes in developing cerebellum include a novel synaptotagmin and a hairless homolog. J Neurosci 16: 7840–7848.

42. Ruike Y, Katsuma S, Hirasawa A, Tsukimoto G (2007) Glucocorticoid-induced alternative promoter usage for a novel 5' variant of granzyme A. J Hum Genet 52: 172–178.

43. Bao BY, Ting HJ, Hsu JW, Lee YF (2008) Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer 122: 2699–2706.

44. Leal TS, Grant MF, Jennings SS, Kaiserich P, Rietveld L, et al. (2003) The gene encoding the Asyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. J Biol Chem 278: 26021–26030.